Am J Transplant, Volume 5, Suppl 3 Archives - Page 79 of 170 - ATC Abstracts

2015 American Transplant Congress
Outcomes Associated With Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) in Solid Organ Transplant (SOT) Recipients
T. Bias,¹ A. Sharma,² G. Malat,³ D. Lee,² A. Doyle.²
¹Dept of Pharmacy, Hahnemann University Hospital, Philadelphia; ²Dept of Medicine, Drexel University, College of Medicine, Philadelphia; ³Dept of Surgery, Drexel University, College of Medicine, Philadelphia, PA.
Background: Infection with CRKP is emerging as an important challenge among SOT recipients. Our study aims to describe the epidemiology and clinical outcomes associated with…
2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
A. Vo, J. Choi, I. Kim, J. Kahwaji, A. Peng, R. Villicana, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…
2015 American Transplant Congress
Monitoring Intracellular Tacrolimus Concentration in Kidney Transplant Recipients With Stable Graft Function
E. Bae,¹ S. Han,¹ S. Yang,² J. Park,¹ H. Lee,¹ J. Lee,³ D. Kim,¹ Y. Kim.¹
¹Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; ²Kidney Research Institute, Seoul National University, Seoul, Korea; ³Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.
Background: Monitoring the intracellular concentration of immunosuppressive agents can be promising to improve and individualize clinical practice in patients receiving transplantation. However, this issue remains…
2015 American Transplant Congress
Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Co-Infected Recipients: The “Real World” Experience
D. Sawinski,¹ G. David,² E. Blumberg,³ P. Abt,⁴ R. Bloom,¹ K. Forde.²
¹Renal Division, Univ. of Penn, Philadelphia, PA; ²Gastroenterology Division, Univ. of Penn, Philadelphia, PA; ³Infectious Disease, Univ. of Penn, Philadelphia, PA; ⁴Surgery, Univ of Penn, Philadelphia, PA.
End stage liver disease is a frequent cause of mortality in patients with HIV. Though demonstrated in the NIH observational trial, the effectiveness of LT…
2015 American Transplant Congress
Identifying the “Operational Tolerant” Pediatric Liver Transplant Recipient by Cytometry by Time-of-Flight
A. Lau,^1,2 M. Vitalone,¹ K. Haas,³ T. Shawler,¹ C. Esquivel,¹ O. Martinez,¹ R. Castillo,³ S. Krams.¹
¹Surgery, Division of Abdominal Transplantation, Stanford University, Stanford, CA; ²Pediatrics, Div. Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco, San Francisco, CA; ³Pediatrics, Div. Gastroenterology, Hepatology, and Nutrition, Stanford University, Stanford, CA.
Liver allografts are known to be well tolerated and indeed, some recipients of liver allografts retain stable graft function in the absence of immunosuppression. The…
2015 American Transplant Congress
Role of Innate Immune Cells in Chronic Allograft Loss and Novel Strategies to Target Them
C. Wu,^1,2 P. Zhao,¹ W. Liu,¹ X. Xiao,¹ X. Shi,¹ Y. Peng,¹ M. Kloc,¹ X. He,² M. Ghobrial,¹ X. Li.¹
¹Center for Immunobiology and Transplantation Research, Houston Methodist Hospital and Houston Methodist Research Institute, Houston, TX; ²Organ Transplant Center, 1st Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Despite remarkable improvements in short term transplant survival, the long-term outcome of allografts remains poor in the clinic, and most transplants are eventually lost due…
2015 American Transplant Congress
A Tool to Estimate Probability of Outcomes on the Liver Transplant Waiting List
A. Hart,^1,2 D. Schladt,¹ J. Zeglin,¹ N. Salkowski,¹ S. Leppke,¹ W. Kim,^1,3 J. Lake,^1,4 A. Israni,¹ B. Kasiske,¹ J. Snyder.¹
¹Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, MN; ²Medicine, Hennepin County Medical Center, Minneapolis, MN; ³School of Medicine, Stanford University, Stanford, CA; ⁴Medicine, University of Minnesota, Minneapolis, MN.
The probability of liver transplant (LTX) and death for candidates varies by donation service area (DSA), making it difficult for candidates to understand the likely…
2015 American Transplant Congress
Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients
A. Seitz,¹ M. Robb,³ S. Balasubramanian,¹ A. McLean,² D. Taube,² R. Johnson,³ R. Baker.¹
¹Renal Unit, St. James's Hospital, Leeds, United Kingdom; ²West London Renal and Transplant, Hammersmith Hospital, London, United Kingdom; ³Organ Donation and Transplantation Studies, NHS Blood and Transplant, Bristol, United Kingdom.
Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…
2015 American Transplant Congress
Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated With Belatacept
W. Kitchens,¹ A. Farris,² S. Pastan,¹ T. Pearson,¹ C. Larsen,¹ A. Adams.¹
¹Emory Transplant Center, Atlanta, GA; ²Department of Pathology, Emory University Hospital, Atlanta, GA.
Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to early allograft loss. A…
2015 American Transplant Congress
Virus Induced CD28 Down-Regulation as a Potential Driver of Costimulation Blockade Resistant Rejection
D. Mou,¹ J. Espinosa,¹ L. Stempora,² J. Kwun,² N. Iwakoshi,¹ A. Kirk.²
¹Surgery, Emory University, Atlanta, GA; ²Surgery, Duke University, Durham, NC.
Belatacept, a B7-specific fusion protein, blocks CD28-B7 costimulation and prevents kidney allograft rejection. However, it is ineffective in a sizable minority of patients. Although T…